Table 5.
Relative risk (95% CI) of diabetes developing within 4 years on the combined effect of AhRL ≥ 2.70 pM and MIS ATP ≤ 88.1% (Group 4).
| Total | Male | Female | |
|---|---|---|---|
| Total number | 168 | 84 | 84 |
| Number of diabetes (%) | 38 (22.6%) | 25 (29.8%) | 13 (15.5%) |
| Model A | 29.82 (12.35–71.99) | 28.18 (9.45–84.02) | 31.68 (6.99–143.45) |
| Model B | 29.34 (12.05–71.44) | 29.36 (9.76–88.35) | 28.33 (6.17–129.95) |
| Model C | 26.12 (10.63–64.17) | 30.35 (9.80–94.02) | 23.99 (5.13–112.24) |
| Model D | 21.11 (8.46–52.67) | 28.43 (8.83–91.58) | 16.50 (3.42–79.67) |
Model A: unadjusted. Model B: sex, age, smoking. Model C: model B + waist circumference and systolic BP-adjusted. Model D: model C + fasting glucose and triglyceride-adjusted. AhRL is expressed as 2,3,7,8-tetrachlorodibenzodioxin (TCDD) equivalents (TCDDeq, pM). MIS-ATP is expressed as % of the 10% charcoal-stripped human serum (CSS)-treated control.